Microphthalmia/Anophthalmia/Coloboma Spectrum – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY
Tanya Bardakjian, MS, LCGC, Avery Weiss, MD, and Adele Schneider, MD, FACMG.
Author Information and AffiliationsInitial Posting: January 29, 2004; Last Update: July 9, 2015.
Estimated reading time: 14 minutes
Summary
NOTE: THIS PUBLICATION HAS BEEN RETIRED. THIS ARCHIVAL VERSION IS FOR HISTORICAL REFERENCE ONLY, AND THE INFORMATION MAY BE OUT OF DATE.
Clinical characteristics.
Microphthalmia, anophthalmia, and coloboma comprise the MAC spectrum of ocular malformations.
Microphthalmia refers to a globe with a total axial length that is at least two standard deviations below the mean for age.
Anophthalmia refers to complete absence of the globe in the presence of ocular adnexa (eyelids, conjunctiva, and lacrimal apparatus).
Coloboma refers to the ocular malformations that result from failure of closure of the optic fissure. Chorioretinal coloboma refers to coloboma of the retina and choroid. Iris coloboma causes the iris to appear keyhole-shaped.
Microphthalmia, anophthalmia, and coloboma may be unilateral or bilateral; when bilateral they may occur in any combination.
Diagnosis/testing.
Molecular genetic testing (which can include sequence analysis, gene-targeted deletion/duplication analysis, and chromosome microarray analysis [CMA]) can identify a genetic cause in 80% of individuals with bilateral anophthalmia/severe microphthalmia and in up to 20% of all individuals with an ocular malformation in the MAC spectrum.
Genetic counseling.
When an inherited or de novo chromosome abnormality or a specific syndrome is identified either by phenotypic findings or by genetic/genomic testing, genetic counseling is indicated based on the mode of inheritance for that condition.
Management.
Treatment of MAC spectrum: Prosthetic intervention is appropriate for those with severe microphthalmia and anophthalmia. In many infants, an ocularist can start shortly after birth to expand the palpebral fissures, conjunctival cul-de-sac, and orbit using conformers of progressively increasing size. An oculoplastic surgeon can help determine the most suitable options for surgical intervention after age six months (when postnatal growth of the orbit can be assessed) and before the age that orbital dimensions are fixed (after which extensive orbital reconstruction may be required).
Children with reduced vision may benefit from visual aids and other visual resources as well as early intervention to help optimize psychomotor development, educational endeavors, life skills, and mobility. Protection of the healthy eye in those with unilateral involvement is recommended.
Definition
Microphthalmia, anophthalmia, and coloboma comprise the MAC spectrum of ocular malformations.
Microphthalmia refers to a globe with a total axial length (TAL) at least two standard deviations below the mean for age (see Table 1).
Table 1.
Length of the Neonatal and Adult Eye
View in own window
Age | Mean Length |
---|
Total Axial Length 1 | Anterior Segment Length 2 | Posterior Segment Length 3 |
---|
Neonate
| 17 mm | 6.8 mm | 10.2 mm |
Adult
| 23.8 mm | 7.3 mm | 16.5 mm |
- 1.
Total axial length (TAL) is the axial distance (in mm) from the corneal apex to the back of the globe.
- 2.
Anterior segment length (ASL) is the axial distance (in mm) from the cornea to the back of the lens.
- 3.
Posterior segment length (PSL) is the axial distance (in mm) from the back of the lens to the back of the globe.
In microphthalmic eyes, measurements of ASL and PSL indicate that ASL is within or below the normal range, whereas PSL is uniformly at least two standard deviations below the mean for age [Weiss et al 1989].
Most postnatal growth of the eye occurs in the first three years of life, particularly during the first year. Growth of the posterior segment accounts for 60% of the prenatal and more than 90% of the postnatal increase in TAL. Although TAL is reduced at birth, the microphthalmic eye can grow by a variable amount in the postnatal period depending on the severity of the underlying malformation.
Classification of microphthalmia is according to the anatomic appearance of the globe and severity of axial length reduction. Severe microphthalmia refers to a globe that is severely reduced in size, with a corneal diameter <4 mm and a TAL <10 mm at birth or <12 mm after age one year. Although the globe is inconspicuous on clinical examination, CT or MRI reveals remnants of ocular tissue, an optic nerve, and extraocular muscles. Without orbital imaging studies, severe microphthalmia can be mistaken for anophthalmia; thus, the term "clinical anophthalmia" is often interchangeably used for severe microphthalmia.
Anophthalmia refers to complete absence of the globe in the presence of ocular adnexa (eyelids, conjunctiva, and lacrimal apparatus).
Coloboma refers to any of the ocular malformations that result from failure of closure of the optic fissure extending inferonasally from the optic disk, retina, and choroid (in the posterior portion of the eye) to the ciliary body and lens zonules and to the iris (in the anterior portion of the eye) during embyrogenesis.
Chorioretinal coloboma refers to coloboma of the retina and choroid. Iris coloboma causes the pupil to be "keyhole" shaped.
Other abnormalities of the eye that can be seen with coloboma include:
Sclerocornea: opacity and vascularization of portions of the normally transparent cornea which, as a result, resembles sclera
Cataract: opacity of the lens
Retinal dysplasia: histologic findings associated with developmental loss of structural and functional cellular components of the retina
Each of these three malformations may be unilateral or bilateral; when bilateral they may occur in any combination. For example:
Colobomatous malformations may occur in any combination within an eye or between eyes of the same individual.
Colobomatous malformations may occur with or without microphthalmia.
Colobomatous malformations in one eye may be accompanied by microphthalmia or anophthalmia in the fellow eye.
Anophthalmia may be bilateral or unilateral with or without colobomatous malformation of the fellow eye.
Establishing the Diagnosis of MAC Spectrum
The diagnosis of MAC is based on the following:
Clinical examination
Gross inspection looking for evidence of a cornea/globe and palpation of the orbit to obtain an estimate of globe size
Measurement of corneal diameter, which normally ranges from 9.0 to 10.5 mm in neonates and 10.5 to 12.0 mm in adults
Imaging study
A-scan ultrasonography to measure total axial length and anterior and posterior segment lengths
B-scan ultrasonography to evaluate the internal structures of the globe
CT scan or MRI of the brain and orbits to evaluate the size and internal structures of the globe, presence of optic nerve and extraocular muscles, and brain anatomy
Differential Diagnosis of MAC Spectrum
Microphthalmia needs to be distinguished from mild microcornea with a normal-sized globe.
Anophthalmia needs to be distinguished from severe microphthalmia, cryptophthalmos, and cystic eye.
Cryptophthalmos ("hidden eye") refers to abnormal fusion of the entire eyelid margin with absence of eyelashes, resulting in a continuous sheet of skin extending from the forehead to the cheek. Failure of eyelid separation can be associated with maldevelopment of the underlying cornea and microphthalmia. Cryptophthalmos is usually bilateral and occurs in association with other multiple malformations collectively referred to as Fraser syndrome (OMIM
219000). Inheritance is autosomal recessive.
Cystic eye refers to a cyst of neuroglial tissue that lacks normal ocular structures. At birth, the cyst may be small, the palpebral fissures narrow, and orbital volume reduced, suggesting anophthalmia. Postnatal expansion of the cyst can lead to distention of the cyst with bulging behind the eyelids. Orbital imaging shows an intraorbital cyst with attached extraocular muscles but no optic nerve. Cystic eye should be distinguished from the cyst associated with colobomatous microphthalmia.
Causes
Recent studies indicate that molecular genetic testing that includes sequence analysis, gene-targeted deletion/duplication analysis, and chromosome microarray analysis (CMA) can identify a genetic cause in:
Chromosome Abnormalities
Chromosome abnormalities can be identified in an estimated 25%-30% of individuals with MAC (Table 2) [Verma & Fitzpatrick 2007].
Table 2.
Common Chromosome Abnormalities Associated with Microphthalmia/Anophthalmia/Coloboma (MAC) Spectrum
View in own window
Type of Chromosome Abnormality | Chromosome Abnormality |
---|
Aneuploidy | Trisomy 9 mosaicism Trisomy 13 Trisomy 18
|
Triploidy | Triploidy |
Deletion |
|
Duplication |
|
Single-Gene Disorders
Single-gene causes of MAC spectrum that account for 1% or more of anophthalmia/microphthalmia/coloboma are listed in Table 3a. Single-gene causes that account for less than 1% of MAC spectrum are listed in Table 3b. The microphthalmia, anophthalmia, and coloboma (MAC) spectrum is present in all disorders listed in both tables.
Of note, the co-occurrence of any of the ocular findings within the MAC spectrum may be unilateral or bilateral and may be in any combination within an eye (e.g., chorioretinal coloboma and/or iris coloboma ± microphthalmia) or between eyes of the same individual (e.g., colobomatous malformation in one eye and anophthalmia in the fellow eye).
Table 3a.
Molecular Genetics of Anophthalmia/Microphthalmia/Coloboma (MAC) Spectrum: Most Common Genetic Causes
View in own window
Gene 1 | Disease Name | % of MAC Attributed to Mutation of This Gene | MOI | Ocular Phenotype 2 | Distinguishing Clinical Features | Selected OMIM |
---|
SOX2
|
SOX2-related eye disorders
| 15%-20% | AD | Optic nerve hypoplasia | FTT, genital abnormalities, pituitary dysfunction, DD, ataxic gait, atypical seizures, SNHL, EA±TEF |
184429
206900
|
OTX2
| OTX2-related eye disorders | 2%-5% | AD | AS; RD; optic nerve hypoplasia/aplasia 3 | Pituitary anomalies/dysfunction, brain abnormalities, DD, autistic features 4 |
600037
610125
|
RAX
| Microphthalmia, isolated 3 | 3% | AR | Sclerocornea | DD |
601881
611038
|
FOXE3
| FOXE3-related ocular disorder 5 | 2.5% | AR | Sclerocornea | Unknown (possible DD, ASD) |
601094
|
BMP4
| Orofacial cleft 11 | 2% | AD | RD; sclerocornea | Digital anomalies, pituitary anomalies/dysfunction, learning disabilities |
112262
600625
|
PAX6
| PAX6-related anophthalmia 6, 7 | 2% | AR | Aniridia | Cerebellar ataxia |
607108
|
BCOR
| Oculofaciocardiodental (OFCD) syndrome 8 | >1% | XL | OFCD: Cataract | OFCD syndrome (females only): cardiac abnormalities, tooth anomaly radiculomegaly, toe anomalies |
300485
300166
|
Lenz microphthalmia syndrome (LMS) | LMS (males only) (see NAA10 in Table 3b) | |
CHD7
|
CHARGE syndrome
| >1% | AD | | Heart defects, choanal atresia, renal anomalies, growth retardation, ear malformations |
608892
214800
|
STRA6
| Microphthalmia, isolated with coloboma 8 | >1% | AR | | Nonsyndromic |
610745
|
Microphthalmia, syndromic 9 (Matthew-Wood syndrome; PDAC) | Congenital diaphragmatic hernia, lung malformations, DD |
601186
|
GDF6
| Microphthalmia, isolated 4 | 1% | AD | | |
601147
613094
|
Klippel-Feil syndrome 1 | Klippel-Feil anomaly, vertebral/rib anomalies, polydactyly |
118100
|
Pathogenic variants of any one of the genes included in this table account for ≥1% of anophthalmia/microphthalmia/coloboma (MAC).
MOI = mode of inheritance
AS = anterior segment dysgenesis; RD = retinal dysplasia
Distinguishing clinical features:
ASD = autism spectrum disorders; DD = developmental delays; EA±TEF = esophageal atresia with or without tracheoesophageal fistula; FTT = failure to thrive; ID = intellectual disability; SNHL = sensorineural hearing loss
- 1.
Genes that cause ≥2% of MAC are listed from most frequent to least frequent genetic cause; they are followed in alphabetic order by genes that cause <2% but >1% of MAC.
- 2.
Ocular features in addition to the typical findings in the MAC spectrum
- 3.
- 4.
- 5.
- 6.
Author [personal observation]
- 7.
Heterozygous PAX6 pathogenic variants are associated with isolated aniridia.
- 8.
Can also be caused by mutation of NAA10 (see Table 3b)
Table 3b.
Molecular Genetics of Anophthalmia/Microphthalmia/Coloboma (MAC) Spectrum: Less Common Genetic Causes
View in own window
Gene 1 | Disease Name | MOI | Ocular Phenotype 2 | Distinguishing Clinical Features | Selected OMIM |
---|
CRYBA4
| Cataract 23 | AD | Cataract | Nonsyndromic |
123631
610425
|
HCCS
|
Microphthalmia with linear skin defects (MIDAS syndrome)
| XL | Sclerocornea | FTT, hydrocephalus, linear pigmentary changes, cardiac & brain anomalies, genital abnormalities |
300056
309801
|
HESX1
| Septooptic dysplasia | AD | Optic nerve hypoplasia | Pituitary hypoplasia, ACC, absence of septum pellucidum |
601802
182230
|
IKBKG
|
Incontinentia pigmenti
| XL | MAC 3 Retinal neovascularization | Skin lesions change w/age; hypodontia, alopecia, dystrophic nails, seizures, ID |
300248
308300
|
NAA10
| Lenz microphthalmia syndrome | XL | | ID, short stature; clavicle, skeletal, & renal anomalies |
300013
309800
|
NHS
| Nance-Horan syndrome | XL | Cataract Microcornea | ID, tooth anomalies, short 4th metacarpal |
300457
302350
|
PORCN
| Focal dermal hypoplasia (Goltz syndrome) | XL | | Atrophic skin patches, cutis aplasia, pigmentary changes, nail anomalies, notched alae nasi, CL/P |
300651
305600
|
PXDN
| See footnote 4 | AR | Sclerocornea | None reported; possible developmental delay | |
RARB
| Microphthalmia, syndromic 12 | AD | | Diaphragmatic hernia, DD, bicornuate uterus, intestinal malrotation, hypotonia |
180220
615524
|
SHH
| Microphthalmia with coloboma 5 | AD | | Nonsyndromic |
600725
611638
142945
|
Holoprosencephaly 5 | Holoprosencephaly, CL/P |
SMOC1
| Microphthalmia with limb anomalies (Waardenburg anophthalmia syndrome) | AR | | Oligosyndactyly, distal limb anomalies, ID |
608488
206920
|
TFAP2A
|
Branchiooculofacial syndrome
| AD | Cataract Ptosis | Branchial skin defect, cleft lip, upper lip pits malformed pinnae, hearing loss |
107580
113620
|
VSX2
| Isolated colobomatous microphthalmia-3 | AR | Cataract | Nonsyndromic |
142993
610092
610093
|
Isolated microphthalmia-2 |
Pathogenic variants in any one of the genes listed in this table are reported in only a few families (i.e., <1% of anophthalmia/microphthalmia/coloboma (MAC).
MOI = mode of inheritance
Distinguishing clinical features:
ACC = absence of the corpus callosum; ASD = autism spectrum disorders; CL/P = cleft lip/palate; DD = developmental delays; EA±TEF = esophageal atresia with or without tracheoesophageal fistula; FTT = failure to thrive; ID = intellectual disability; SNHL = sensorineural hearing loss
- 1.
Genes are listed in alphabetic order.
- 2.
Ocular features in addition to the typical findings in the MAC spectrum
- 3.
- 4.
- 5.
Evaluation Strategy
Establishing the specific genetic cause of microphthalmia/anophthalmia/coloboma (MAC) spectrum in a given individual usually involves the following:
Ophthalmologic examination by an ophthalmologist familiar with MAC to document both the ocular manifestations of MAC and any additional ocular findings.
Ocular/brain imaging studies
Physical examination (including dysmorphology examination) to determine the presence of distinguishing clinical features which may identify a specific genetic cause (see
Tables 3a and
3b). Additional studies that may be warranted include:
Family history. It is appropriate to obtain a three-generation family history of eye anomalies, including anophthalmia, microphthalmia, and coloboma. Complete eye examination of both parents is warranted.
Genomic/genetic testing, which can include the following:
Chromosomal microarray analysis (CMA) to look for evidence of aneuploidy or chromosome duplication, deletion, or rearrangement (
Table 2). Note: CMA will not detect balanced chromosomal rearrangements.
Single-gene testing in the order in which genes are most likely to be mutated, based on the individual’s clinical findings and/or family history (see
Table 3a and
Table 3b). Single-gene testing should include sequence analysis as well as gene-targeted deletion/duplication analysis [
Reis et al 2010,
Chassaing et al 2014].
Use of a multigene panel that includes the genes of interest. Note: (1) The genes included and the sensitivity of multigene panels vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
For an introduction to multigene panels click
here. More detailed information for clinicians ordering genetic tests can be found
here.
More comprehensive genomic testing (when available) including exome sequencing, genome sequencing, and mitochondrial sequencing may be considered if serial single-gene testing (and/or use of a multigene panel) fails to confirm a diagnosis in an individual with MAC spectrum.
For an introduction to comprehensive genomic testing click
here. More detailed information for clinicians ordering genomic testing can be found
here.
If no diagnosis is established after the initial set of examinations and tests, reevaluation within two years is recommended.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members; it is not meant to address all personal, cultural, or
ethical issues that may arise or to substitute for consultation with a genetics
professional. —ED.
When an inherited or de novo chromosome abnormality (see Table 2) or a specific syndrome is identified either by features listed in Table 3a or Table 3b or by genetic/genomic testing, genetic counseling is indicated based on the mode of inheritance for that condition.
Prenatal Testing
Pregnancies known to be at increased risk for MAC spectrum due to a previous affected child
and/or family history
If the genetic/genomic cause has been identified in the affected relative, prenatal testing relies on testing that will detect the genetic/genomic change present in the affected relative.
If the genetic/genomic cause has not been identified in the affected relative, prenatal testing relies on the following imaging studies:
Transvaginal ultrasound examination may identify the eyes from 12 weeks' gestation onward [
Chen et al 2003,
Mashiach et al 2004]. In most reports, eye malformations are detected only after 22 weeks' gestation. The sensitivity of transvaginal ultrasound examination in detecting anophthalmia/microphthalmia is not known [
Wong et al 2008].
Pregnancies not known to be at increased risk for MAC spectrum. When a MAC spectrum abnormality is detected on fetal ultrasound examination, further diagnostic work up is recommended including chromosome microarray analysis (CMA) and SOX2 sequence analysis and gene-targeted deletion/duplication analysis. Use of a multigene panel of genes of interest can also be considered.
Preimplantation genetic testing may be an option for some families in which pathogenic variant(s) in a specific gene have been identified.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click here.
International Children's Anophthalmia and Microphthalmia Network (ICAN)
c/o Center for Developmental Medicine and Genetics
5501 Old York Road
Genetics, Levy 2 West
Philadelphia PA 19141
Phone: 800-580-4226 (toll-free)
Email: ican@anophthalmia.org
National Eye Institute
31 Center Drive
MSC 2510
Bethesda MD 20892-2510
Phone: 301-496-5248
Email: 2020@nei.nih.gov
National Federation of the Blind (NFB)
200 East Wells Street
(at Jernigan Place)
Baltimore MD 21230
Phone: 410-659-9314
Fax: 410-685-5653
Email: pmaurer@nfb.org
eyeGENE - National Ophthalmic Disease Genotyping Network Registry
Phone: 301-435-3032
Email: eyeGENEinfo@nei.nih.gov
Management
Treatment of MAC Spectrum
Prosthetic intervention is appropriate in severe microphthalmia and anophthalmia.
In many infants, an ocularist can start shortly after birth to expand the palpebral fissures, conjunctival cul-de-sac, and orbit using conformers of progressively increasing size. In some instances, conformers do not adequately expand the orbit, especially horizontally, causing an "hour glass" deformity.
An oculoplastic surgeon can help determine the most suitable options for surgical intervention after age six months (when postnatal growth of the orbit can be assessed) and before the age that orbital dimensions are fixed (after which extensive orbital reconstruction may be required).
Surgical options include placement of orbital implants of fixed dimensions at one or more surgeries; placement of expandable implants (silicone balloon, hydrophilic polymers); or use of a dermis-fat graft, which has the capability of post-surgical growth.
Children with reduced vision may benefit from visual aids and other visual resources as well as early intervention to help optimize psychomotor development, educational endeavors, life skills, and mobility. Protection of the healthy eye in those with unilateral involvement is recommended.
References
Literature Cited
Araujo Júnior E, Kawanami TE, Nardozza LM, Milani HJ, Oliveira PS, Moron AF. Prenatal diagnosis of bilateral anophthalmia by 3D "reverse face" view ultrasound and magnetic resonance imaging.
Taiwan J Obstet Gynecol. 2012;51:616–9. [
PubMed: 23276567]
Chassaing N, Causse A, Vigouroux A, Delahaye A, Alessandri JL, Boespflug-Tanguy O, Boute-Benejean O, Dollfus H, Duban-Bedu B, Gilbert-Dussardier B, Giuliano F, Gonzales M, Holder-Espinasse M, Isidor B, Jacquemont ML, Lacombe D, Martin-Coignard D, Mathieu-Dramard M, Odent S, Picone O, Pinson L, Quelin C, Sigaudy S, Toutain A, Thauvin-Robinet C, Kaplan J, Calvas P. Molecular findings and clinical data in a cohort of 150 patients with anophthalmia/microphthalmia.
Clin Genet. 2014;86:326–34. [
PubMed: 24033328]
Chen CP, Wang KG, Huang JK, Chang TY, Lin YH, Chin DT, Tzen CY, Wang W. Prenatal diagnosis of otocephaly with microphthalmia/anophthalmia using ultrasound and magnetic resonance imaging.
Ultrasound Obstet Gynecol. 2003;22:214–5. [
PubMed: 12905522]
Choi A, Lao R, Ling-Fung Tang P, Wan E, Mayer W, Bardakjian T, Shaw GM, Kwok PY, Schneider A, Slavotinek A. Novel mutations in PXDN cause microphthalmia and anterior segment dysgenesis.
Eur J Hum Genet. 2015;23:337–41. [
PMC free article: PMC4326713] [
PubMed: 24939590]
Gordon RA, Donzis PB. Refractive development of the human eye.
Arch Ophthalmol. 1985;103:785–9. [
PubMed: 4004614]
Islam L, Kelberman D, Williamson L, Lewis N, Glindzicz MB, Nischal KK, Sowden JC. Functional analysis of FOXE3 mutations causing dominant and recessive ocular anterior segment disease.
Hum Mutat. 2015;36:296–300. [
PubMed: 25504734]
Jimenez NL, Flannick J, Yahyavi M, Li J, Bardakjian T, Tonkin L, Schneider A, Sherr EH, Slavotinek AM. Targeted 'next-generation' sequencing in anophthalmia and microphthalmia patients confirms SOX2, OTX2 and FOXE3 mutations.
BMC Med Genet. 2011;12:172. [
PMC free article: PMC3262754] [
PubMed: 22204637]
Khan K, Rudkin A, Parry DA, Burdon KP, McKibbin M, Logan CV, Abdelhamed ZI, Muecke JS, Fernandez-Fuentes N, Laurie KJ, Shires M, Fogarty R, Carr IM, Poulter JA, Morgan JE, Mohamed MD, Jafri H, Raashid Y, Meng N, Piseth H, Toomes C, Casson RJ, Taylor GR, Hammerton M, Sheridan E, Johnson CA, Inglehearn CF, Craig JE, Ali M. Homozygous mutations in PXDN cause congenital cataract, corneal opacity, and developmental glaucoma.
Am J Hum Genet. 2011;89:464–73. [
PMC free article: PMC3169830] [
PubMed: 21907015]
Lee A, Deutinger J, Bernaschek G. Three dimensional ultrasound: abnormalities of the fetal face in surface and volume rendering mode.
Br J Obstet Gynaecol. 1995;102:302–6. [
PubMed: 7612513]
Mashiach R, Vardimon D, Kaplan B, Shalev J, Meizner I. Early sonographic detection of recurrent fetal eye anomalies.
Ultrasound Obstet Gynecol. 2004;24:640–3. [
PubMed: 15517557]
Minić S, Obradović M, Kovacević I, Trpinac D. Ocular anomalies in incontinentia pigmenti: literature review and meta-analysis.
Srp Arh Celok Lek. 2010;138:408–13. [
PubMed: 20842883]
Reis LM, Tyler R, Schneider A, Bardakjian T, Semina E. Examination of SOX2 in variable ocular conditions identified a recurrent deletion in microphthalmia and lack of mutations in other phenotypes.
Mol Vis. 2010;16:768–73. [
PMC free article: PMC2862242] [
PubMed: 20454695]
Schilter KF, Schneider A, Bardakjian T, Soucy JF, Tyler RC, Reis LM, Semina EV. OTX2 microphthalmia syndrome: four novel mutations and delineation of a phenotype.
Clin Genet. 2011;79:158–68. [
PMC free article: PMC3017659] [
PubMed: 20486942]
Weiss AH, Kousseff BG, Ross EA, Longbottom J. Simple microphthalmos.
Arch Ophthalmol. 1989;107:1625–30. [
PubMed: 2818284]
Williamson KA, FitzPatrick DR. The genetic architecture of microphthalmia, anophthalmia and coloboma.
Eur J Med Genet. 2014;57:369–80. [
PubMed: 24859618]
Wong HS, Parker S, Tait J, Pringle KC. Antenatal diagnosis of anophthalmia by three-dimensional ultrasound: a novel application of the reverse face view.
Ultrasound Obstet Gynecol. 2008;32:103–5. [
PubMed: 18570241]
Chapter Notes
Revision History
7 November 2019 (ma) Chapter retired: outdated
9 July 2015 (me) Comprehensive update posted live – title change
15 February 2007 (cd) Revision: testing for mutations in RAX clinically available
26 May 2006 (me) Comprehensive update posted live
29 January 2004 (me) Overview posted live
7 March 2003 (as) Original submission